DE69631605D1 - Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen - Google Patents
Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinenInfo
- Publication number
- DE69631605D1 DE69631605D1 DE69631605T DE69631605T DE69631605D1 DE 69631605 D1 DE69631605 D1 DE 69631605D1 DE 69631605 T DE69631605 T DE 69631605T DE 69631605 T DE69631605 T DE 69631605T DE 69631605 D1 DE69631605 D1 DE 69631605D1
- Authority
- DE
- Germany
- Prior art keywords
- proteins
- lipids
- preparing
- reducing
- blood levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51626395A | 1995-08-17 | 1995-08-17 | |
US516263 | 1995-08-17 | ||
PCT/US1996/012674 WO1997006816A1 (en) | 1995-08-17 | 1996-08-02 | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69631605D1 true DE69631605D1 (de) | 2004-03-25 |
DE69631605T2 DE69631605T2 (de) | 2005-01-05 |
Family
ID=24054813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69631605T Expired - Fee Related DE69631605T2 (de) | 1995-08-17 | 1996-08-02 | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020147142A1 (de) |
EP (1) | EP0865294B1 (de) |
JP (1) | JP4173913B2 (de) |
AT (1) | ATE259650T1 (de) |
AU (1) | AU6688896A (de) |
CA (1) | CA2229450A1 (de) |
DE (1) | DE69631605T2 (de) |
DK (1) | DK0865294T3 (de) |
ES (1) | ES2216055T3 (de) |
MX (1) | MX9801159A (de) |
PT (1) | PT865294E (de) |
WO (1) | WO1997006816A1 (de) |
ZA (1) | ZA966798B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
EP0833835A4 (de) * | 1995-06-22 | 1999-05-26 | Lilly Co Eli | Obesitätsprotein zwischenprodukte, ihre herstellung und verwendung |
US5830450A (en) * | 1996-06-19 | 1998-11-03 | Lallone; Roger L. | Compositions of leptin bound to an apolipoprotein |
US7332338B2 (en) | 1996-10-04 | 2008-02-19 | Lexicon Pharmaceuticals, Inc. | Vectors for making genomic modifications |
US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US6808921B1 (en) | 1998-03-27 | 2004-10-26 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
US6436707B1 (en) | 1998-03-27 | 2002-08-20 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
DE69921486T2 (de) * | 1998-08-10 | 2006-02-02 | Amgen Inc., Thousand Oaks | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
EP1214351A2 (de) * | 1999-09-22 | 2002-06-19 | Genset | Verfahren zur selektion von verbindungen, die die wechselwirkung zwischen leptin und lsr modulieren, und ihre verwendung für die verhütung und behandlung von fettsuchtverwandten krankheiten |
EP2219031B1 (de) | 2001-10-22 | 2013-04-24 | Amgen, Inc. | Verwendung von Leptin zur Behandlung von Lipoatrophie im Menschen und Verfahren zur Bestimmung einer Prädisposition gegenüber der Behandlung |
DE60334787D1 (de) | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | Substituierte amide |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
GB0307367D0 (en) * | 2003-03-29 | 2003-05-07 | Twg | Composition and method for treating the gastro-intestinal tract |
EP1462116A1 (de) * | 2003-03-29 | 2004-09-29 | Villitech SARL | Zubereitung zur Behandlung des Magen-Darm-Traktes |
JP2007517042A (ja) | 2003-12-30 | 2007-06-28 | デュレクト コーポレーション | 活性物質、好ましくはgnrhの制御放出のための、好ましくはpegおよびplgの混合物を含有するポリマーインプラント |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
EP1814590B2 (de) | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Behandlung von fettsucht und verbundenen erkrankungen |
US7629315B2 (en) * | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
CA3138758A1 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Llc | Highly soluble leptins |
BR112015006848A2 (pt) | 2012-09-27 | 2018-05-22 | Childrens Medical Ct Corp | formulação farmacêutica, método de indução de perda de peso, método de redução de gordura corporal, método de redução de ingesta de comida, método para melhorar homeostase de glicose e método para prevenir um aumento do índice de massa corporal de um paciente normal, pré-obeso, obeso ou obeso mórbido. |
LT3074033T (lt) | 2013-11-26 | 2019-02-25 | The Children`S Medical Center Corporation | Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai |
US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
EP3509624B1 (de) | 2016-09-12 | 2023-08-09 | Amryt Pharmaceuticals Inc. | Verfahren zum nachweis von anti-leptin-neutralisierenden antikörpern |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
-
1996
- 1996-08-02 CA CA002229450A patent/CA2229450A1/en not_active Abandoned
- 1996-08-02 WO PCT/US1996/012674 patent/WO1997006816A1/en active IP Right Grant
- 1996-08-02 DK DK96926873T patent/DK0865294T3/da active
- 1996-08-02 AT AT96926873T patent/ATE259650T1/de not_active IP Right Cessation
- 1996-08-02 EP EP96926873A patent/EP0865294B1/de not_active Expired - Lifetime
- 1996-08-02 DE DE69631605T patent/DE69631605T2/de not_active Expired - Fee Related
- 1996-08-02 JP JP50931997A patent/JP4173913B2/ja not_active Expired - Fee Related
- 1996-08-02 AU AU66888/96A patent/AU6688896A/en not_active Abandoned
- 1996-08-02 MX MX9801159A patent/MX9801159A/es not_active IP Right Cessation
- 1996-08-02 ES ES96926873T patent/ES2216055T3/es not_active Expired - Lifetime
- 1996-08-02 PT PT96926873T patent/PT865294E/pt unknown
- 1996-08-12 ZA ZA9606798A patent/ZA966798B/xx unknown
-
2001
- 2001-05-07 US US09/850,433 patent/US20020147142A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0865294A1 (de) | 1998-09-23 |
MX9801159A (es) | 1998-05-31 |
JP4173913B2 (ja) | 2008-10-29 |
AU6688896A (en) | 1997-03-12 |
JPH11511165A (ja) | 1999-09-28 |
ZA966798B (en) | 1997-02-19 |
WO1997006816A1 (en) | 1997-02-27 |
ATE259650T1 (de) | 2004-03-15 |
DK0865294T3 (da) | 2004-06-28 |
ES2216055T3 (es) | 2004-10-16 |
PT865294E (pt) | 2004-07-30 |
EP0865294B1 (de) | 2004-02-18 |
CA2229450A1 (en) | 1997-02-27 |
US20020147142A1 (en) | 2002-10-10 |
DE69631605T2 (de) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69631605D1 (de) | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen | |
ATE326476T1 (de) | Verfahren zur herstellung von phosphorothioat- oligomeren | |
ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
ATE202940T1 (de) | Mittel und methoden zur behandlung von plaque- krankheiten | |
ATE510552T1 (de) | Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
NO995843L (no) | Farmasoeytisk preparat omfattende vWF-propeptid | |
ATE181422T1 (de) | Verfahren zur diagnose von praeklampsie | |
PT804562E (pt) | Factor 2 de crescimento de tecido conjuntivo | |
ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE69829217D1 (de) | Vorrichtung zur therapeutischen behandlung von blutgefässen | |
DE69619187D1 (de) | Verfahren zur behandlung von motorischen defiziten | |
DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
DE50010234D1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
DE60023555D1 (de) | Verfahren zur behandlung von gewebe | |
ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
DE3865484D1 (de) | Verfahren zur herstellung von urantetrafluorid und von schwefelfluoriden mittels redoktion von uranhexafluorid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |